Chengming et al. demonstrated that mutated KRAS NSCLC showed an inflammatory phenotype with adaptive immune resistance, characterized by an increased proportion of CD8+ tumor-infiltrating lymphocytes (TILs) and high tumor mutational burden (TMB) [23]. Here, KRAS is linked to neoplasm.